To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

NCT06646354 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension
Primary Hypercholesterolaemia

Interventions

DRUG: Ezetimibe/Rosuvastatin/Candesartan/Amlodipine
DRUG: Candesartan/Amlodipine
DRUG: Candesartan/Rosuvastatin/Ezetimibe

Sponsor

Hyundai Pharm